SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients

Geers, Daryl, Shamier, Marc C., Bogers, Susanne, den Hartog, Gerco, Gommers, Lennert, Nieuwkoop, Nella N., Schmitz, Katharina S., Rijsbergen, Laurine C. +17 more·2021·Science Immunology
DOI 10.1126/sciimmunol.abj1750

Cited by (421)

Items 301–400 of 421

  1. Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses
    A. Ogbe, M. Pace, M. Bittaye et al. · 2021
  2. A bivalent COVID-19 mRNA vaccine elicited broad immune responses and protection against Omicron subvariants infection
    Jun Liu, Li Wang, Alexandra Kurtesi, Patrick Budylowski, Kyle G. Potts, Haritha Menon, Yilin Tan, Philip Samaan, Xinan Liu, Yisen Wang et al. · 2025 · npj Vaccines
  3. Structural Insights on the SARS-CoV-2 Variants of Concern Spike Glycoprotein: A Computational Study With Possible Clinical Implications
    Marni E. Cueno, Kenichi Imai · 2021 · Frontiers in Genetics
  4. SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern
    Natália Satchiko Hojo-Souza, Júlia Teixeira de Castro, Graziella Gomes Rivelli, Patrick Orestes de Azevedo, Emiliano Rosa Oliveira, Lídia Faustino, Natália Salazar, Flávia Fonseca Bagno, Alex Fiorini de Carvalho, Bruna Amanda da Cruz Rattis et al. · 2024 · Vaccine
  5. Mechanistic models of humoral kinetics following COVID-19 vaccination
    Daniel Stocks, Amy C Thomas, Adam H.R. Finn, León Danon, Ellen Brooks‐Pollock · 2025 · Journal of The Royal Society Interface
  6. Vaccination and COVID-19: impact on long-COVID
    Gustavo N. Guimarães, N. S. Brunetti, D. G. de Lima, J. L. Proença-Módena, Alessandro S. Farias · 2025 · Frontiers in Immunology
  7. Double-layered N-S1 protein nanoparticle immunization elicits robust cellular immune and broad antibody responses against SARS-CoV-2
    Ruiqi Li, Zejie Chang, Hongliang Liu, Yanan Wang, Minghui Li, Yilan Chen, Fan Lü, Siqiao Wang, Xueke Sun, Siyuan John Liu et al. · 2024 · Journal of Nanobiotechnology
  8. A self-amplifying mRNA COVID-19 vaccine drives potent and broad immune responses at low doses that protects non-human primates against SARS-CoV-2
    Amy Rappaport, Sue‐Jean Hong, Ciaran D. Scallan, Leonid Gitlin, Arvin Akoopie, Gregory R. Boucher, Milana Egorova, J. Aaron Espinosa, Mario Fidanza, Melissa A. Kachura et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  9. Cell-mediated and humoral immune response to SARS-CoV-2 vaccination and booster dose in immunosuppressed patients
    Lu M. Yang, C. Costales, M. Ramanathan et al. · 2022 · medRxiv
  10. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program
    Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, Godelieve J. de Bree, Judith Potjewijd, Abraham Rutgers, Hetty Jolink, Frank L. van de Veerdonk, Marit J. van Gils et al. · 2024 · Frontiers in Immunology
  11. Mutations of SARS-CoV-2 variants of concern escaping Spike-specific T cells
    Nina Le Bert, Anthony Tanoto Tan, Kamini Kunasegaran, Adeline Chia, Nicole Tan, Qi Chen, Shou Kit Hang, Martin Qui, Bianca Su-Wan Chan, Jenny Guek Hong Low et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  12. Accuracy of interferon gamma release assays for the COVID-19 immunity assessment
    F. Stieber, Nadia P. C. Allen, K. Carpenter · 2022 · Journal of Virological Methods
  13. RBD mutations at the residues K417, E484, N501 reduced immunoreactivity with antisera from vaccinated and COVID-19 recovered patients
    Dablu Lal Gupta, Jhasaketan Meher, Anjan Kumar Giri, Arvind Kumar Shukla, Eli Mohapatra, Manisha Ruikar, DN Rao · 2024 · Drug Target Insights
  14. Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters
    Junyu Chen, Congjie Chen, Lunzhi Yuan, Yaode Chen, Ningxin Tang, Ningxin Tang, Dongmei Wei, Xiangzhong Ye, Ningshao Xia, Yixin Chen · 2024 · PNAS Nexus
  15. Hybrid immunity-based induction of durable pan-endemic-coronavirus immunity in the elderly
    Lucie Loyal, Julian Braun, Ulf Reimer, Lil Meyer‐Arndt, Larissa Henze, Beate Kruse, Manuela Dingeldey, Maike Mangold, Janina Ruth Behrens, Pinkus Tober‐Lau et al. · 2025 · Cell Reports
  16. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa
    William C. McMahon, G. Kwatra, A. Izu et al. · 2022 · AIDS (London)
  17. SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies
    Jordi Cámara, Aída González-Díaz, Irene Barrabeig, Miguel Fernández-Huerta, Laura Calatayud, Jordí Niubó, Sara Martí, M.Á. Domínguez, Carmen Ardanuy · 2022 · Vaccine
  18. Limited Impact of Delta Variant’s Mutations on the Effectiveness of Neutralization Conferred by Natural Infection or COVID-19 Vaccines in a Latino Population
    Carlos A. Sariol, Crisanta Serrano-Collazo, Edwin J. Ortiz, Petraleigh Pantoja, Lorna A. Cruz, Teresa Arana, Dianne Atehortua, Christina Pabon-Carrero, Ana Margarita Espino · 2021 · Viruses
  19. A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants
    Ya-Hui Zhang, Mei-Jing Feng, Yong-Mei He, Fang-Ming Liu, Rui Ma · 2022 · Frontiers in Public Health
  20. Incidence and Severity of COVID-19 in Relation to Anti-Receptor-Binding Domain IgG Antibody Level after COVID-19 Vaccination in Kidney Transplant Recipients
    A. Lianne Messchendorp, Jan‐Stephan Sanders, Alferso C Abrahams, Fréderike J. Bemelman, Pim Bouwmans, René M. A. van den Dorpel, Luuk B. Hilbrands, Céline Imhof, Marlies E. J. Reinders, Theo Rispens et al. · 2024 · Viruses
  21. Humoral and cell-mediated immune responses to BNT162b2 vaccine against SARS-CoV-2 in people with cystic fibrosis
    Gianfranco Alicandro, Béatrice Silvia Orena, Chiara Rosazza, Lisa Cariani, Maria Chiara Russo, Michela Zatelli, Raffaele Badolato, Andrea Gramegna, Francesco Blasi, Valeria Daccò · 2023 · Vaccine
  22. Dynamics of the Delta and Omicron variants of SARS-CoV-2 in the United States: the battle of supremacy in the presence of vaccination, mask usage and antiviral treatment
    C. Ngonghala, H. B. Taboe, A. Gumel · 2022 · medRxiv
  23. Vaccine Response in the Immunocompromised Patient with Focus on Cellular Immunity
    C. Bahrs, N. Harrison · 2022 · Vaccines
  24. Improved Performance of the QuantiFERON-SARS-CoV-2 Assay with the Extended Set
    Lydia Lamara Mahammed, Kahina Bensaid, Sarah Ait-Seddik, Amel Larinouna, Ghania Brahimi, Rosa Belkaid, Ouassila Hamzaoui, Soumia Meriem Rouaki, Cherifa Idder, Ines Allam et al. · 2023 · Viruses
  25. Cytomegalovirus-vectored COVID-19 vaccines elicit neutralizing antibodies against the SARS-CoV-2 Omicron variant (BA.2) in mice
    Jian Liu, Dabbu Kumar Jaijyan, Yanling Chen, Changcan Feng, Shaomin Yang, Zhenglong Xu, Nichun Zhan, Congming Hong, Shuxuan Li, Tong Cheng et al. · 2023 · Microbiology Spectrum
  26. Single-dose respiratory mucosal delivery of next-generation viral-vectored COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2
    S. Afkhami, M. D'Agostino, Ali Zhang et al. · 2021 · bioRxiv
  27. Can B cell‐deficient patients rely on COVID ‐19 vaccine‐induced T‐cell immunity?
    Tanaya Shree · 2022 · British Journal of Haematology
  28. Humoral and cellular immune responses after COVID-19 vaccination of lung transplant recipients and patients on the waiting list: a 6-month follow-up
    R. Hoek, Siqi Liu, C. Geurtsvankessel et al. · 2024 · Frontiers in Immunology
  29. SARS-CoV-2-Specific T-Cell as a Potent Therapeutic Strategy against Immune Evasion of Emerging COVID-19 Variants
    Keon-Il Im, Nayoun Kim, Jun-Seok Lee, Ui-Hyeon Oh, Hye Won Lee, Dong‐Gun Lee, Gi June Min, Raeseok Lee, JinAh Lee, Seungtaek Kim et al. · 2024 · International Journal of Molecular Sciences
  30. Humoral and T-cell–mediated immunity to SARS-CoV-2 vaccination in patients with liver disease and transplant recipients
    Alexandra N. Willauer, Susan D. Rouster, Heidi L. Meeds, Carrie L. Jennings, Enass A. Abdel-hameed, Diane E. Daria, Elizabeth Stambrook, Mohamed Tarek M. Shata, Kenneth E. Sherman · 2023 · Hepatology Communications
  31. In-silico evaluation of the T-cell based immune response against SARS-CoV-2 omicron variants
    Shivangi Sharma, Diya Roy, Sarah Cherian · 2024 · Scientific Reports
  32. Evaluation of bivalent Omicron BA.1 booster vaccination after different priming regimens in healthcare workers (SWITCH ON): a randomized controlled trial
    N. Tan, D. Geers, R. Sablerolles et al. · 2022 · medRxiv
  33. Highly Networked SARS-CoV-2 Peptides Elicit T Cell Responses with Enhanced Specificity
    Gabriel Duette, Eunok Lee, Gabriela Martins Costa Gomes, Katie Tungatt, Chloe M. Doyle, Vicki V Stylianou, Ashley Lee, Susan Maddocks, Janette Taylor, Rajiv Khanna et al. · 2023 · ImmunoHorizons
  34. Prospective SARS-CoV-2 additional vaccination in immunosuppressant-treated individuals with autoimmune diseases in a randomized controlled trial
    Meggan C. Mackay, Catriona A. Wagner, Ashley Pinckney, Jeffrey A. Cohen, Zachary Scott Wallace, Arezou Khosroshahi, Jeffrey A. Sparks, Sandra M. Lord, Amit Saxena, Roberto Caricchio et al. · 2025 · JCI Insight
  35. Performance of T-Track® SARS-CoV-2, an Innovative Dual Marker RT-qPCR-Based Whole-Blood Assay for the Detection of SARS-CoV-2-Reactive T Cells
    Franziska M. Kanis, Johannes P. Meier, Harald Guldan, Hans-Helmut Niller, Michael Dahm, Alexander Dansard, Thomas Zander, Friedhelm Struck, Erwin Soutschek, Ludwig Deml et al. · 2023 · Diagnostics
  36. COVID-19: A Systematic Review of the Transmissibility, Pathogenesis, Entry Factors, and Signature Immune Response
    Deena Fayyad, Jessica L. Kelts, Tristan H. Nielson, Ibiere Lovelyn Epelle, Nicodemus C. Monear, Miguel T. G. Strawn, Benjamin N. Woerner, Besa Xhabija · 2022 · BioChem
  37. T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine
    Kirk D. Haltaufderhyde, Andrés H. Gutiérrez, Mitchell McAllister, Christine Boyle, Leonard Moise, William D Martin, Anne Searls De Groot · 2025 · Human Vaccines & Immunotherapeutics
  38. The Long-Term Immunogenicity of mRNABNT162b Third Vaccine Dose in Solid Organ Transplant Recipients
    Maria Antonella Zingaropoli, Mariasilvia Guardiani, Federica Dominelli, Eeva Tortellini, Manuela Garofalo, Francesco Cogliati Dezza, Anastasia Centofanti, Carolina Carillo, Anna Napoli, Federico Venuta et al. · 2024 · Vaccines
  39. An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results
    Marzena Zalewska−Ziob, Wiktoria Fus, Adam Konka, Karolina Wystyrk, Aneta Bochenek, Hanna Botor, Martyna Fronczek, Joanna Zembala-John, Brygida Adamek · 2022 · Vaccines
  40. Seropositivity to Nucleoprotein to detect SARS-CoV-2 infections: a tool to detect breakthrough infections after COVID-19 vaccination
    2021
  41. Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once‐boosted BA.1/2 convalescents and twice‐boosted COVID‐19‐naïve individuals
    Chang Kyung Kang, Min‐Gang Kim, Seong‐wook Park, Yong‐Woo Kim, Chan Mi Lee, Pyoeng Gyun Choe, Wan Beom Park, Nam Joong Kim, Minji Kim, Soojin Lee et al. · 2023 · Journal of Medical Virology
  42. IL-10/IL-6 ratio from nasal & oral swab samples, acts as an inflammatory indicator for COVID-19 patients infected with the delta variant
    Biswajit Kumar Biswas, Subhanita Roy, Indranath Banerjee, Subhasis Jana, Bornali Bhattacharjee, Suman Kumar Chakraborty, Arindam Mondal, Ritobrata Goswami · 2023 · Heliyon
  43. Structural patterns of SARS-CoV-2 variants of concern (alpha, beta, gamma, delta) spike protein are influenced by variant-specific amino acid mutations: A computational study with implications on viral evolution
    Marni E. Cueno, Kanta Wada, Arisa Tsuji, Kouta Ishikawa, Kenichi Imai · 2022 · Journal of Theoretical Biology
  44. T-cell responses to SARS-CoV-2 vaccinations in adults with Down syndrome – a prospective cohort study
    Lobke C.M. Hensen, Bianca M. M. Streng, Femke van Wijk, Stefan Nierkens, Rob S. van Binnendijk, Anne‐Marie Buisman, Antonia M. W. Coppus, Corine H. GeurtsvanKessel, Gert de Graaf, Fiona R.M. van der Klis et al. · 2025 · Human Vaccines & Immunotherapeutics
  45. Live attenuated COVID-19 vaccines: approaches to development and prospects for clinical use
    E. R. Korchevaya, Anastasiia V. Gracheva, Ilya N. Dyakov, В. В. Зверев, Е. Б. Файзулоев · 2023 · Journal of microbiology epidemiology immunobiology
  46. Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies, pro-inflammatory cytokines, NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study
    M. Hema Prashaad, R. Siew, A. Aw et al. · 2025 · Therapeutic Advances in Infectious Disease
  47. Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
    Chuan Chen, James W. Saville, Michelle M. Martí, Alexandra Schäfer, Mary Hongying Cheng, Dhiraj Mannar, Xing Quan Zhu, Alison Berezuk, Anupam Banerjee, Michele D. Sobolewski et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  48. Potent and dose-sparing next-generation SARS-CoV-2 vaccine, mRNA-1283, induces polyfunctional and durable T cell immunity
    Yamuna Devi Paila, Rolando Pajón, Barbara L. Banbury, Paul Fields, Maha Maglinao, Stephen C. De Rosa, Daryl E. Morris, M. Juliana McElrath, Umaporn Siangphoe, Kristen W. Cohen et al. · 2026 · npj Vaccines
  49. Enhanced immunity after Ad26.COV2.S vaccine breakthrough infection
    David C. Montefiori · 2022 · Cell Reports Medicine
  50. Longitudinal Characterization of a Neutralizing and Total Antibody Response in Patients with Severe COVID-19 and Fatal Outcomes
    Ricardo Serna-Muñoz, Alejandra Hernández‐Terán, Maribel Soto-Nava, Daniela Tapia‐Trejo, Santiago Ávila‐Ríos, Fidencio Mejía-Nepomuceno, Emma García, Manuel de Jesús Castillejos-López, Anjarath Lorena Higuera-Iglesias, Arnoldo Aquino‐Gálvez et al. · 2022 · Vaccines
  51. Humoral and Cellular Response Induced by Primary Series and Booster Doses of mRNA Coronavirus Disease 2019 Vaccine in Patients with Cardiovascular Disease: A Longitudinal Study
    Yuya Ishihara, Hiroyuki Naruse, Hidetsugu Fujigaki, Reiko Murakami, Tatsuya Ando, Kouhei Sakurai, Komei Uehara, Koki Shimomae, Eirin Sakaguchi, Hidekazu Hattori et al. · 2024 · Vaccines
  52. Seroprevalence of SARS-CoV-2 antibodies among healthcare workers in Dutch hospitals after the 2020 first wave: a multicentre cross-sectional study with prospective follow-up
    Claudia Recanatini, Corine H. GeurtsvanKessel, Suzan D. Pas, Els M. Broens, Martje L. Maas, Rosa van Mansfeld, Anne Mutsaers-van Oudheusden, Miranda van Rijen, Emile F. Schippers, Arjan Stegeman et al. · 2023 · Antimicrobial Resistance and Infection Control
  53. Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022
    Paz Beatriz Tabilo Tabilo Valenzuela, Gabriela Flores Flores Balter, Gustavo Saint-Pierre Saint-Pierre Contreras · 2022 · Life
  54. Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome
    Bianca M. M. Streng, Lobke C.M. Hensen, Eveline M. Delemarre, Rob S. van Binnendijk, Gaby P. Smits, Gerco den Hartog, Fiona R.M. van der Klis, Esther de Vries, Judith A. Burger, Marit J. van Gils et al. · 2025 · Vaccine
  55. Heterologous prime-boost vaccination with VLA2001 and an ORFV-based vector enhances spike- and nucleocapsid-specific immunity in mice
    A. Reguzova, Verena Haug, Carina Metz · 2025 · Frontiers in Immunology
  56. Humoral and cellular immune response after severe acute respiratory syndrome coronavirus 2 messenger ribonucleic acid vaccination in heart transplant recipients: An observational study in France
    Alice Casenaz, S. Grosjean, S. Aho · 2022 · Frontiers in Medicine
  57. The need for more holistic immune profiling in next-generation SARS-CoV-2 vaccine trials
    Robert L. Murphy, Eustache Paramithiotis, Scott Sugden, Todd Chermak, Bruce L. Lambert, Damien Montamat‐Sicotte, John E. Mattison, Steven R. Steinhubl · 2022 · Frontiers in Immunology
  58. Revealing the significance of IL-2 and IL-5 in SARS-CoV-2-specific T-cell responses in kidney transplant recipients
    Yvette den Hartog, S. Reshwan K. Malahe, Wim J. R. Rietdijk, Marjolein Dieterich, Lennert Gommers, Debbie van Baarle, Dimitri Adriaan Diavatopoulos, A. Lianne Messchendorp, Renate G.V.D. Molen, Ester B. M. Remmerswaal et al. · 2024 · npj Viruses
  59. Systematic Determinants of Global COVID-19 Burden: Longitudinal Time-Series Analysis Using Big Data-Driven Artificial Intelligence
    Zi-Cheng Cao, Wen-Jie Han, Xue Zhang, Chi Zhang, Jin-Feng Zeng, Yi-Lin Chen, Hao-Yu Long, Jian Chen, Xiang-Jun Du · 2025 · Journal of Medical Internet Research
  60. Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies
    Tomáš Milota, Jitka Smetanová, Jiřina Bartůňková · 2023 · Pathogens
  61. The BNT162b2 mRNA vaccine induces polyfunctional T cell responses with features of longevity
    G. Guerrera, M. Picozza, Silvia D’Orso et al. · 2021 · bioRxiv
  62. Optimisation of SARS-CoV-2 peptide stimulation and measurement of cytokine output by intracellular flow cytometry and bio-plex analysis
    Jemma Victoria Taylor, Emma L. Callery, Anthony W. Rowbottom · 2023 · Journal of Immunological Methods
  63. Detection of humoral and cellular immune response to anti-SARS-CoV-2 BNT162b2 vaccine in breastfeeding women and naïve and previously infected individuals
    Milena R. Cavic, Andrijana Nešić, Katarina Mirjačić Martinović, Ana M. Vuletić, Irina Besu, Nevena Tišma Miletić, Ana Krivokuća, Radmila N. Jankovic, Marija Đ. Gavrović-Jankulović · 2023 · Scientific Reports
  64. Reduced spike specific T-cell responses in COVID-19 vaccinated subjects undergoing SARS-CoV-2 breakthrough infection
    Stefania Varchetta, Federica Sole Golfetto, Patrizia Bono, Annapaola Callegaro, Tanya Fabbris, Andrea Favalli, Mariacristina Crosti, Tullia Maria De Feo, Nathalie Iannotti, Giorgio Bozzi et al. · 2025 · Frontiers in Immunology
  65. Immunity to a third BNT162B2 COVID-19 vaccine after heart transplantation: Bridging the knowledge gap to end the pandemic for organ transplant recipients
    G. Haidar · 2022 · The Journal of Heart and Lung Transplantation
  66. Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID‐19 booster dose in persons with HIV
    Giulia Matusali, Alessandra Vergori, Eleonora Cimini, Davide Mariotti, Valentina Mazzotta, Alessandro Cozzi‐Lepri, Francesca Colavita, Roberta Gagliardini, Stefania Notari, Silvia Meschi et al. · 2024 · Journal of Medical Virology
  67. Intradermal Fractional ChAdOx1 nCoV-19 Booster Vaccine Induces Memory T Cells: A Follow-Up Study
    Ratchanon Sophonmanee, Perawas Preampruchcha, Jomkwan Ongarj · 2024 · Vaccines
  68. Uptake of SARS-CoV-2 workplace testing programs, March 2020 to March 2021
    Nathan Duarte, Sean D'Mello, Natalie A. Duarte · 2021 · medRxiv
  69. Fear-Responses to Bat-Originating Coronavirus Pandemics with Respect to Quarantines Gauged in Relation to Postmodern Thought—Implications and Recommendations
    Carol Nash · 2022 · COVID
  70. SARS-CoV-2-specific B cell responses in non-draining lymph nodes and antibody functionalities in immunized end-stage renal disease patients
    Sophie C. Frölke, Daryl Geers, Kenney Gino Amirkhan, Danisha Sri Pathmarajah, Nelly D. van der Bom‐Baylon, Mirza M. Idu, Marit J. van Gils, Mathieu A. F. Claireaux, Suzanne E. Geerlings, Theo Rispens et al. · 2025 · Scientific Reports
  71. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome
    Anouk E. M. Nouwen, Luca M. Zaeck, Renske Schappin, Daryl Geers, Lennert Gommers, Susanne Bogers, Willem A. Dik, Suzanne G.M.A. Pasmans, Corine H. GeurtsvanKessel, Rory D. de Vries et al. · 2024 · Journal of Clinical Immunology
  72. CoviWall, a whole-virion-inactivated B.1.617.2 vaccine candidate, induces potent humoral and Th1 cell response in mice and protects against B.1.617.2 strain challenge in Syrian hamsters
    Jyotsna Dandotiya, Neeta Adhikari, Manas Ranjan Tripathy, Kamini Jakhar, Sudipta Sonar, Dibya Ranjan Pati, Vibhu Kanchan, Varsha S. Prasad, Jitendra Kumar, Nitesh K. Senapati et al. · 2025 · Frontiers in Immunology
  73. Humoral and cellular immune responses to mRNA COVID-19 vaccinations in the elderly: A longitudinal study in Japan
    Kiyoyasu Fukushima, Toru Kubo, Yuta Ito, Yoshie Oda, Yohsuke Nagayoshi, Minoru Fukuda, Takahiro Takazono, Noriho Sakamoto, Hiroshi Mukae · 2025 · Journal of Infection and Chemotherapy
  74. Mechanistic models of humoral kinetics following COVID-19 vaccination
    L. Danon, E. Brooks-Pollock, Amy C. Thomas · 2024 · medRxiv
  75. SARS-CoV-2 vaccines elicit differential Fc effector functions
    Nelia P. Manamela, Boitumelo M. Motsoeneng, Holly Spencer, Tandile Hermanus, Nonkululeko B. Mzindle, Frances Ayres, Zanele Makhado, Rudolph Serage, Glenda Gray, Linda‐Gail Bekker et al. · 2025 · iScience
  76. Broad and robust T cell immunity compensates the population immune barrier against antibody-escaping Omicron variants
    Yuanyuan Guo, Peipei Guo, Jinmin Tian, Yeerzati Tuluhongtayi, Rui Song, George F. Gao, Xin Zhao, Jun Liu · 2026 · Frontiers in Immunology
  77. Three-dose mRNA-1273 vaccination schedule: sufficient antibody response in majority of immunocompromised hematology patients
    Sabine Haggenburg, Quincy Hofsink, Birgit Ilja Lissenberg-Witte, Annoek E. C. Broers, Jaap A. van Doesum, Rob S. van Binnendijk, Gerco den Hartog, Michel S. Bhoekhan, Nienke J.E. Haverkate, Judith A. Burger et al. · 2022 · medRxiv
  78. Patterns of restricted TCR usage following SARS-CoV-2 vaccination and severe disease
    Emily L. Parsons, Zhongyan Lu, Stephanie A Richard, Amanda E Zelkoski, Janifer Le, Naraen Palanikumar, Phuong Nguyen, Camille Alba, Gauthaman Sukumar, John G. Rosenberger et al. · 2025 · Frontiers in Immunology
  79. Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers
    Lucrezia Puccini, M. Fantini, C. Biagetti et al. · 2023 · Frontiers in Microbiology
  80. SARS-CoV-2 Spike S1-specific IgG kinetic profiles following mRNA- versus vector-based vaccination in the general Dutch population
    L. L. van den Hoogen, M. Verheul, E. Vos et al. · 2021 · medRxiv
  81. Precise motif and cross-presentation of coronavirus peptides by feline MHC class I: implications for the mild infection of SARS-CoV-2.
    Peiwen Qiao, C. Yue, Weiyu Peng et al. · 2025 · Journal of Immunology
  82. Inactivated vaccine fueled adaptive immune responses to Omicron in 2‐year COVID‐19 convalescents
    Maoshun Liu, Jie Zhang, Lei Li, Lei Li, Mengjie Yang, Bingli Shang, Xin Wang, Jinmin Tian, Hongmei Li, Hong Li et al. · 2023 · Journal of Medical Virology
  83. Functional analyses and single cell immunoprofiling uncover sex-specific differences in SARS-CoV2 immune memory development
    Basak Eraslan, Eric Brown, Maura E. Benson, Liat Amir-Zilberstein, Sung‐Moo Park, Betsabeh Khoramian Tusi, Vladislav Pokatayev, Cody J.S. Hecht, Novalia Pishesha, Devan Phillips et al. · 2022 · Research Square
  84. Using the vesicular stomatitis virus vector (rVSV vector) platform for SARS-CoV-2 vaccine development: Phase 1/2 safety and immunogenicity of IIBR-100 in healthy adults
    Yoseph Caraco, Noa Madar-Balakirski, Eytan Ben‐Ami et al. · 2025 · Vaccine
  85. Bibliometric analysis of the highly cited publications in COVID-19 vaccine
    Li Yan, Lihua Liu · 2023 · Heliyon
  86. The Cellular and Humoral Immune Response to SARS-CoV-2 Messenger RNA Vaccines Is Significantly Better in Liver Transplant Patients Compared with Kidney Transplant Patients
    Anja Lautem, Simone Cosima Boedecker-Lips, Elisa Schneider, Stefan Runkel, Christina Feist, Hauke Lang, Julia Weinmann‐Menke, Martina Koch · 2023 · Pathogens
  87. Limited induction of lung-resident memory T cell responses against SARS-CoV-2 by mRNA vaccination
    Daan K. J. Pieren, Sebastián G. Kuguel, J. Rosado · 2022 · medRxiv
  88. Development of an ultrahigh affinity, trimeric ACE2 biologic as a universal SARS-CoV-2 antagonist
    Juliet Elizabeth Gonzales, Tynan Young, Hyeran Choi, Miso Park, Yead Jewel, Chengcheng Fan, Rahul Purohit, Pamela J. Björkman, John C. Williams · 2025 · Communications Biology
  89. Sustained immunological memory to SARS-CoV-2 antigens. Three years of observation
    Zulfiia E. Afridonova, А. П. Топтыгина, Elena L. Semikina · 2024 · Russian Journal of Infection and Immunity
  90. SARS-CoV-2 Nsp1 Is a Major Suppressor of HLA Class I and Class II Expression
    Ivo Schirmeister, Nicolas Eckert, Sebastian Weigang, Jonas Fuchs, Lisa Kern, Georg Kochs, Anne Halenius · 2025 · Viruses
  91. Triple COVID-19 vaccination induces humoral and cellular immunity to SARS-CoV-2 with cross-recognition of the Omicron variant and IgA secretion
    Louisa Ruhl, Jenny F. Kühne, Kerstin Beushausen, Jana Keil, Stella Christoph, Jasper Sauer, Christine Susanne Falk · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  92. SARS-CoV-2-Antikörper-Antwort auf die zweite COVID-19-Impfung bei neuromuskulären Patienten unter immunmodulierender Therapie
    Seyed Siyawasch Justus Lattau, Anna Dudakova, Karsten Kummer, Jana Zschüntzsch · 2022 · Der Nervenarzt
  93. Analysis of islet antigen-specific autoreactive T cells from Japanese patients with slowly progressive insulin-dependent diabetes mellitus
    Noriyuki Kitagawa, Nobuko Kitagawa, Ayaka Kobayashi · 2025 · Immunology Letters
  94. Transmission of mutated SARS-CoV-2 variants is favored by relatively prolonged infections due to delayed immunity
    Katherine Owens, Pierce E. Radecki, S. Tempia · 2026 · bioRxiv
  95. mRNA-based COVID-19 vaccination of lung transplant recipients with prior SARS-CoV-2 infection induces durable SARS-CoV-2-specific antibodies and T cells.
    Siqi Liu, L. V. van Dijk, Yvette den Hartog · 2024 · Vaccine
  96. Humoral and Cellular Immune Response in Patients with Hematological Disorders After Three Doses of mRNA COVID-19 Vaccine: A Single-Center Observational Study
    Rosa Daffini, Francesco Zecchini, Giulia Venneri · 2026 · Vaccines
  97. COVID-19 boosters restore virus-specific immune responses in kidney transplant recipients unresponsive to primary vaccination
    Yvette den Hartog, Yannick van Sleen, Lennert Gommers, Luca M. Zaeck, Daryl Geers, A. Lianne Messchendorp, Jan‐Stephan Sanders, Carla C. Baan, Debbie van Baarle, Rory D. de Vries et al. · 2026 · npj Viruses
  98. Analysis of the Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Breast Cancer Patients Treated With Cyclin-Dependent Kinases 4 and 6 Inhibitors (CDKi): Limited T-Cell Immunity Despite Satisfactory Humoral Response.
    Cristina Saavedra, Alejandro Vallejo, Federico Longo, Juan Jose Serrano Domingo, María Fernández, María Gión, Elena López-Miranda, Noelia Martínez-Jáñez, Eva Guerra, Jesús Chamorro et al. · 2021 · Research Square
  99. The Efficacy and Safety of SARS-CoV-2 Vaccinations in People with Multiple Sclerosis
    E. Roberts · 2023 · EMJ Neurology
  100. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients
    M. Raadsen, C. Visser, A. H. Ayesha Lavell et al. · 2023 · Vaccines